Brief: Belite Bio Announces U.S. Food And Drug Administration Acceptance And Priority Review Of New Drug Application For Tinlarebant For The Treatment Of Stargardt Disease Type 1
11/08/2026 21:49
BRIEF-Belite Bio Announces U.S. Food And Drug Administration Acceptance And Priority Review Of New Drug Application For Tinlarebant For The Treatment Of Stargardt Disease Type 1 Aug 11 (Reuters) - Belite Bio, Inc BLTE.O:
BELITE BIO ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE TYPE 1
BELITE BIO - FDA SETS PDUFA DATE OF FEBRUARY 12, 2027 FOR TINLAREBANT NDA
Source text: ID:nGNX6NS1M4
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses